Clinical Trial

THC, Cannabis, and Psychosis

Study Description

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I

The overall purpose of this study is to examine the effect of Pregnenolone (PREG) on the acute psychosis-like and cognitive effects of Delta-9-Tetrahydrocannabinol (THC). This will be tested by pretreating healthy individuals with PREG, and then assessing their responses to Dronabinol (THC).

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Active Dronabinol

20 mg capsule of Dronabinol will be administered orally

Drug - Active Pregnenolone

1.79 mg/kg of Pregnenolone will be administered sublingually (under the tongue)

Drug - Placebo Dronabinol

Control: Placebo pill (no active cannabinoids) administered orally

Drug - Placebo Pregnenolone

Control: Placebo given sublingually (under the tongue)

Additional Information

Official Study Title

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I

Clinical Trial ID

NCT02811939

ParticipAid ID

9aAr9b